CLINICAL BENEFITS OF EICOSAPENTAENOIC ACID IN HUMANS

摘要

Methods are provided for maintaining or lowering lipoprotein-associated phospholipase A2 ["Lp-PLA2"] levels, stabilizing rupture prone-atherosclerotic lesions, decreasing the Inflammatory Index and increasing Total Omega-3 scoreTM in humans, by administering an effective amount of eicosapentaenoic acid ["EPA"], an omega-3 polyunsaturated fatty acid ["PUFA"].